Market Closed -
London S.E.
09:30:01 2024-02-05 am EST
|
5-day change
|
1st Jan Change
|
3.375
GBX
|
-2.17%
|
|
-.--%
|
-3.57%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
27.22
|
32.44
|
31.52
|
67.37
|
17.4
|
5.174
|
Enterprise Value (EV)
1 |
-10.2
|
6.051
|
19.76
|
45.89
|
3.418
|
-1.558
|
P/E ratio
|
-1.55
x
|
-2.27
x
|
-2.76
x
|
-4.09
x
|
-1.79
x
|
-0.96
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
30.3
x
|
11.9
x
|
5.11
x
|
262
x
|
43.2
x
|
9.76
x
|
EV / Revenue
|
-11.4
x
|
2.22
x
|
3.21
x
|
179
x
|
8.48
x
|
-2.94
x
|
EV / EBITDA
|
0.51
x
|
-0.34
x
|
-1.4
x
|
-3.6
x
|
-0.31
x
|
0.22
x
|
EV / FCF
|
0.96
x
|
-0.74
x
|
-1.73
x
|
-13.8
x
|
-0.7
x
|
0.25
x
|
FCF Yield
|
104%
|
-135%
|
-57.9%
|
-7.25%
|
-142%
|
404%
|
Price to Book
|
0.74
x
|
1.39
x
|
2.38
x
|
3.56
x
|
1.76
x
|
1.02
x
|
Nbr of stocks (in thousands)
|
31,646
|
31,646
|
31,834
|
56,856
|
57,064
|
57,174
|
Reference price
2 |
0.8600
|
1.025
|
0.9900
|
1.185
|
0.3050
|
0.0905
|
Announcement Date
|
7/31/18
|
8/3/19
|
8/19/20
|
8/17/21
|
8/16/22
|
6/16/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.897
|
2.72
|
6.165
|
0.257
|
0.403
|
0.53
|
EBITDA
1 |
-20.14
|
-18
|
-14.12
|
-12.73
|
-11
|
-6.945
|
EBIT
1 |
-20.38
|
-18.28
|
-14.41
|
-12.99
|
-11.23
|
-7.115
|
Operating Margin
|
-2,271.57%
|
-672.13%
|
-233.72%
|
-5,055.25%
|
-2,786.1%
|
-1,342.45%
|
Earnings before Tax (EBT)
1 |
-20.97
|
-17.18
|
-13.86
|
-13.41
|
-11.06
|
-6.657
|
Net income
1 |
-17.62
|
-14.29
|
-11.41
|
-11.35
|
-9.689
|
-5.408
|
Net margin
|
-1,963.77%
|
-525.44%
|
-185.11%
|
-4,415.18%
|
-2,404.22%
|
-1,020.38%
|
EPS
2 |
-0.5566
|
-0.4516
|
-0.3587
|
-0.2900
|
-0.1701
|
-0.0947
|
Free Cash Flow
1 |
-10.58
|
-8.159
|
-11.44
|
-3.328
|
-4.868
|
-6.299
|
FCF margin
|
-1,180.04%
|
-299.97%
|
-185.51%
|
-1,294.94%
|
-1,207.97%
|
-1,188.56%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/31/18
|
8/3/19
|
8/19/20
|
8/17/21
|
8/16/22
|
6/16/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
37.4
|
26.4
|
11.8
|
21.5
|
14
|
6.73
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-10.6
|
-8.16
|
-11.4
|
-3.33
|
-4.87
|
-6.3
|
ROE (net income / shareholders' equity)
|
-39.2%
|
-47.6%
|
-62.6%
|
-70.6%
|
-67.3%
|
-72.4%
|
ROA (Net income/ Total Assets)
|
-25.1%
|
-31.1%
|
-34.7%
|
-35.5%
|
-32.9%
|
-33%
|
Assets
1 |
70.18
|
45.95
|
32.88
|
31.95
|
29.46
|
16.4
|
Book Value Per Share
2 |
1.160
|
0.7400
|
0.4200
|
0.3300
|
0.1700
|
0.0900
|
Cash Flow per Share
2 |
0.8800
|
0.6500
|
0.4000
|
0.2600
|
0.1700
|
0.1100
|
Capex
1 |
0.24
|
0.19
|
0.12
|
0.03
|
0.3
|
0.22
|
Capex / Sales
|
26.2%
|
6.91%
|
1.93%
|
9.73%
|
74.94%
|
41.51%
|
Announcement Date
|
7/31/18
|
8/3/19
|
8/19/20
|
8/17/21
|
8/16/22
|
6/16/23
|
|
1st Jan change
|
Capi.
|
---|
| -3.57% | 2.41M | | +23.37% | 46.71B | | +48.83% | 41.8B | | -0.94% | 41.52B | | -5.86% | 29.55B | | +11.29% | 25.78B | | -20.92% | 19.26B | | +3.20% | 12.14B | | -2.67% | 12.08B | | +30.23% | 11.98B |
Other Biotechnology & Medical Research
|